Alnylam Gross Profit Margin from 2010 to 2024

ALNY Stock  USD 250.98  6.09  2.49%   
Alnylam Pharmaceuticals Gross Profit Margin yearly trend continues to be fairly stable with very little volatility. Gross Profit Margin is likely to outpace its year average in 2024. During the period from 2010 to 2024, Alnylam Pharmaceuticals Gross Profit Margin regression line of annual values had r-squared of  0.06 and arithmetic mean of  0.87. View All Fundamentals
 
Gross Profit Margin  
First Reported
2010-12-31
Previous Quarter
0.83022077
Current Value
0.96
Quarterly Volatility
0.04371323
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 56.8 M, Interest Expense of 127.3 M or Other Operating Expenses of 2.2 B, as well as many indicators such as Price To Sales Ratio of 12.42, Dividend Yield of 0.0 or Days Sales Outstanding of 63.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Gross Profit Margin Growth Pattern

Below is the plot of the Gross Profit Margin of Alnylam Pharmaceuticals over the last few years. It is Alnylam Pharmaceuticals' Gross Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Gross Profit Margin10 Years Trend
Pretty Stable
   Gross Profit Margin   
       Timeline  

Alnylam Gross Profit Margin Regression Statistics

Arithmetic Mean0.87
Geometric Mean0.86
Coefficient Of Variation5.05
Mean Deviation0.03
Median0.85
Standard Deviation0.04
Sample Variance0
Range0.1457
R-Value0.24
Mean Square Error0
R-Squared0.06
Significance0.39
Slope0
Total Sum of Squares0.03

Alnylam Gross Profit Margin History

2024 0.96
2021 0.83
2020 0.84
2019 0.89
2018 0.98

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Gross Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Gross Profit Margin 0.83  0.96 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.